Multi‐Targeted Kinase Inhibitor Therapy in Pediatric Bone and Soft Tissue Sarcoma Patients—A Single Centre Experience
Cancer Medicine · 2025
DOI: 10.1002/cam4.70951 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Anna Mohás und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Centre, Tűzoltó Street Department, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Bone Neoplasms, Protein Kinase Inhibitors, Sarcoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with relapsed or refractory soft tissue and bone sarcomas have dismal outcomes. Multi‐targeted kinase inhibitors (mTKI) have proven to be potent agents in several malignancies, both as primer therapy and as a salvage option. Our aim was to evaluate the clinical outcomes of mTKI treatment in a heterogeneous group of pediatric sarcoma patients retrospectively. Procedures A total of 18 patients were treated with sorafenib, regorafenib, or pazopanib; 13 of them had osteosarcoma (OSC), 3 had synovial sarcoma (SySa), and 1–1 patient had chondrosarcoma and rhabdomyosarcoma. Indication for mTKI treatment was primarily progressive, inoperable, relapsed, or chemotherapy‐resistant disease after completion of first‐ and second‐line chemotherapy.
Results
At the time of the beginning of mTKI treatment, the median age was 16.5 years, and the median time to progression from initiation of mTKI was 4 months. The overall response rate was 16%. We conducted a comparison of the survival outcomes of OSC patients receiving mTKIs against a retrospective, non‐randomized control group. Overall survival was evaluated from the time of progression or relapse after second‐line treatment to the time of death. The log‐rank test revealed a significant difference in the survival distribution between patients receiving mTKIs and those who did not (chi2(1) = 8.13 p = 0.004). We observed benefits from mTKI treatment in 3 SySa patients, with pazopanib demonstrating effectiveness and no progression observed thus far.
Conclusions
Our findings suggest that mTKIs are well‐tolerated and can serve as a therapeutic option for refractory bone sarcomas as palliative treatment, aiming to slow disease progression and uphold a good quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Centre, Tűzoltó Street Department, Semmelweis University, Budapest, Hungary.
- National Childhood Cancer Registry (NCCR), Hungarian Pediatric Oncology Network (HuPON). Department of Paediatrics, Semmelweis University, Budapest, Hungary.
ORCID-Profile: Anna Mohás
Zitieren
APA
Mohás, A., Horváth, K., Jakab, Z., & Csóka, M. (2025). Multi‐Targeted Kinase Inhibitor Therapy in Pediatric Bone and Soft Tissue Sarcoma Patients—A Single Centre Experience. Cancer Medicine. https://doi.org/10.1002/cam4.70951
Vancouver
Mohás A, Horváth K, Jakab Z, Csóka M. Multi‐Targeted Kinase Inhibitor Therapy in Pediatric Bone and Soft Tissue Sarcoma Patients—A Single Centre Experience. Cancer Medicine. 2025. doi:10.1002/cam4.70951
BibTeX
@article{Mohs2025,
author = {Mohás, Anna and Horváth, Klára and Jakab, Zsuzsanna and Csóka, Monika},
title = {Multi‐Targeted Kinase Inhibitor Therapy in Pediatric Bone and Soft Tissue Sarcoma Patients—A Single Centre Experience},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70951}
}
EUVIMED